Copyright
©The Author(s) 2019.
World J Gastroenterol. Jun 7, 2019; 25(21): 2581-2590
Published online Jun 7, 2019. doi: 10.3748/wjg.v25.i21.2581
Published online Jun 7, 2019. doi: 10.3748/wjg.v25.i21.2581
Table 1 Depicts pre-clinical demographic and clinical data and post-operative changes to symptoms and gastric emptying
Article | Shlomovitz et al[25], 2014 | Gonzalez et al[26], 2017 | Kahaleh et al[27], 2018 | Rodriguez et al[28], 2017 | Rodriguez et al[29], 2018 | Malik et al[30], 2018 | Jacques et al[31], 2017 | Dacha et al[32], 2017 | Mekaroonkamol et al[33], 2018 | Khashab et al[34], 2017 |
n | 7 | 29 | 33 | 47 | 100 | 13 | 20 | 16 | 30 | 30 |
Female (%) | 100 | 65.50 | 66 | 78.70 | 85.00 | 53.58 | — | 81.25 | 86.70 | 57 |
Age (mean) | 51 | 52.8 | 52 | 43.7 | 45 | 45.7 | — | 44.76 | 47 | 47 |
Previous gastric stim | — | 4 (13.8%) | 2 (6%) | 16 (34.0%) | 20 (20%) | 3 (23%) | 0 | 4 (25%) | 4 (13.3%) | 0 |
Previous botox treatment | — | 1 (3%) | 4 (12%) | 28 (59.6%) | 46 (46%) | 11 (84.6%) | 2 (10%) | 0 | 1 (3%) | 12 (40%) |
Pre GES 4 h (mean %) | 21 | 40 ± 34 | 45 | 37.2 ± 25.1 | 39 ± 26.5 | 49 ± 24 | 57 | 62.5 | 63.0 ± 25.5 | 37 |
Pre GCSI | 3.3 ± 0.9 | 4.61 | 3.8 ± 0.86 | 2.2 ± 0.8 | 3.5 | 3.41 | 3.5 ± 0.6 | |||
Gastroparesis: Idiopathic | 4 | 15 | 12 | 27 | 56 | 4 | 4 | 5 | 12 | 7 |
Gastroparesis: Diabetes | 0 | 7 | 7 | 12 | 21 | 1 | 10 | 9 | 12 | 11 |
Gastroparesis: Post-surgical | 2 | 5 | 12 | 8 | 19 | 8 | 1 | 1 | 5 | 12 |
Gastroparesis: Scleroderma | 0 | 2 | 2 | — | — | — | 1 | 0 | 0 | 0 |
Total of major postoperative complications | 4/7 | 5/29 | 1/33 | 0/47 | 10/100 | 1/13 | 3/20 | 0/16 | 1 | 2/30 |
Post GES Residual 4 hours | 4% | 28 ± 45 | 17% ± 17 | 20.4 ± 26.1 | 16.3 ± 21.4 | 33 ± 28 | 15 | 25.4 | 22.2 ± 20.5 | 17% ± 16 |
Symptom improvement | 85.70% | 69% | 86% | — | — | 73% | 90% | 81% | 76.70% | 86% |
How defined improvement | Clinical improvement | Decrease in GCSI | Clinical improvement1 | Not defined | Not defined | CPGAS score | GCSI decrease by 0.75 | Decrease in GCSI | Decrease in GCSI2 | Clinical improvement |
Length of follow up (mo) | 6.5 | 6 | 6 | 3 | 3 | 3 | 3 | 12 | 6-18 | 6 |
Timing of F/u GES in days | 84 | 56 | — | 90 | 90 | 84 | 84 | 56 | 42-56 | 81-105 |
GES improvement | 4/5 (90%) | 23/29 (79.3%) | — | — | 78% α | 4/6 (66.7%) | 19/20 (95%) | 12/12 (100%) | 78.3%α | 14/17, 82.3% |
Normalization of GES | 0/5 | 16/29 | 4/6 | — | 57% α | 0 | 6/20 | 9/12 | 47.8%α | 8/17 |
- Citation: Podboy A, Hwang JH, Nguyen LA, Garcia P, Zikos TA, Kamal A, Triadafilopoulos G, Clarke JO. Gastric per-oral endoscopic myotomy: Current status and future directions. World J Gastroenterol 2019; 25(21): 2581-2590
- URL: https://www.wjgnet.com/1007-9327/full/v25/i21/2581.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i21.2581